IMPORTANT UPDATE FOR CYTODYN SPECIAL MEETING OF STOCKHOLDERS
Change in Location of the Special Meeting to be held on July 22, 2020
Meeting Date: July 22, 2020
Meeting Time:
9:30 a.m. (Pacific Time)
Meeting Access: http://www.meetingcenter.io/285700571
VANCOUVER, Washington, July 08, 2020 (GLOBAL NEWSWIRE)—Due to the emerging public health impact of the coronavirus outbreak (COVID-19) and to support the health and well-being of our employees, stockholders, and our community please note that the CytoDyn Inc. Special Meeting of Stockholders will be held on July 22, 2020 in virtual
format only. In person attendance at the Special Meeting by stockholders will not be permitted.
To access the virtual meeting please click the Virtual
Stockholder Meeting link. To login to the virtual meeting, you have two options: Join as a “Guest” or Join as a “Stockholder.” If you join as a “Stockholder,” you will be required to have a control number and
password to login to the virtual meeting. The password for the meeting is CYDY2020.
If you were a stockholder as of the close of business on
June 17, 2020 and have your control number, you may vote during the Special Meeting by following the instructions available on the meeting website during the meeting. For registered stockholders, the control number can be found on your proxy
card or notice, or email you previously received.
If you hold your shares through an intermediary, such as a bank or broker, you must register in advance
to attend the Special Meeting. To register you must submit proof of your proxy power (legal proxy) reflecting your CytoDyn Inc. holdings along with your name and email address to Computershare. Requests for registration must be labeled as
“Legal Proxy” and be received no later than 5:00 p.m., Eastern Time, on July 17, 2020. You will receive a confirmation email from Computershare of your registration.
Requests for registration should be directed to Computershare at the following address:
By email:
Forward the email from your broker, or
attach an image of your legal proxy, to legalproxy@computershare.com
If you do not have your control number, you may attend as a guest but will
not have the option to vote your shares or ask questions at the virtual meeting.
Stockholders are reminded to vote their shares whether they plan to
attend the virtual meeting or not. Stockholders may vote their shares in advance of the meeting by one of the methods described in CytoDyn’s Proxy Statement filed with the SEC on June 22, 2020.
Please note that the proxy card included with the proxy materials previously distributed will not be updated to reflect the change in location and may
continue to be used to vote your shares in connection with the Special Meeting.
About CytoDyn
CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized
monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor
metastasis and immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected
treatment-experienced patients. CytoDyn filed its BLA in April 2020 to seek FDA approval for leronlimab as a combination therapy for highly treatment experienced HIV patients, and submitted additional FDA requested clinical datasets on May 11,
2020. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab
monotherapy indication. If successful, it could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV. No drug-related serious site
injection reactions reported in about 800 patients treated with leronlimab and no drug-related SAEs reported in patients treated with 700 mg dose of leronlimab. Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent
viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for
the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is at www.cytodyn.com.